Adam Lee Maddox

Dr. Adam Lee Maddox

City of Hope, Duarte, California, USA
orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 November 2019 in Journal of Extracellular Vesicles
Verified
Journal Article
Open access
KLKathleen Lennon
Kathleen Lennon
DWDevin Wakefield
Devin Wakefield
Adam Lee MaddoxAdam Lee Maddox
Adam Lee Maddox
MBMatthew S. Brehove
Matthew S. Brehove
AWAri N. Willner
Ari N. Willner
TJTijana Jovanovic-Talisman
Tijana Jovanovic-Talisman
Biofluid‐accessible extracellular vesicles (EVs) may represent a new means to improve the sensitivity and specificity of detecting disease. However, current methods to isolate EVs encounter challenges when they are used to select specific populations. Moreover, it has been difficult to comprehensively characterize heterogeneous EV populations at the single vesicle level. Here, we robustly assessed heterogeneous EV populations from cultured cell lines via nanoparticle tracking analysis, proteomics, transcriptomics, transmission electron microscopy, and quantitative single molecule localization microscopy (qSMLM). Using qSMLM, we quantified the size and biomarker content of individual EVs. We applied qSMLM to patient plasma samples and identified a pancreatic cancer‐enriched EV population. Our goal is to advance single molecule characterization of EVs for early disease detection.Abbreviations: EV: Extracellular Vesicle; qSMLM: quantitative Single Molecule Localization Microscopy; PDAC: Pancreatic Ductal Adenocarcinoma; EGFR: epidermal growth factor receptor 1; CA19‐9: carbohydrate antigen 19‐9; SEC: size exclusion chromatography; WGA: wheat germ agglutinin; AF647: Alexa Fluor 647; Ab: antibody; HPDEC: Healthy Pancreatic Ductal Epithelial Cell; TEM: Transmission Electron Microscopy.

18 August 2015 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
DBDeepali Bhandari
Deepali Bhandari
ILInmaculada Lopez-Sanchez
Inmaculada Lopez-Sanchez
ATAndrew To
Andrew To
ILI-Chung Lo
I-Chung Lo
NANicolas Aznar
Nicolas Aznar
PGPradipta Ghosh
Pradipta Ghosh
Significance: The guanine nucleotide exchange factor (GEF) GIV/Girdin has previously been shown to trigger noncanonical activation of trimeric G proteins in response to multiple chemical stimuli at the plasma membrane and at various locations within cells. In this work we identified a single phosphoevent and pinpointed cyclin-dependent kinase 5 (CDK5) as the responsible kinase that activates GIV's GEF function and initiates noncanonical G protein signaling via GIV. These studies provide evidence that CDK5 is essential for maximal activation of GIV-GEF in cells and insights into a hitherto unrecognized crosstalk between CDK5 and G proteins via GIV. Such crosstalk may shape migration–proliferation dichotomy during several physiological and pathological scenarios such as wound healing and cancer metastasis.

4 June 2022 in Cancers
Verified
Journal Article
Open access
PDF file
Adam Lee MaddoxAdam Lee Maddox
Adam Lee Maddox
MBMatthew S. Brehove
Matthew S. Brehove
KEKiarash R. Eliato
Kiarash R. Eliato
ASAndras Saftics
Andras Saftics
EREugenia Romano
Eugenia Romano
TJTijana Jovanovic-Talisman
Tijana Jovanovic-Talisman
Trastuzumab, the prototype HER2-directed therapy, has markedly improved survival for women with HER2-positive breast cancers. However, only 40–60% of women with HER2-positive breast cancers achieve a complete pathological response to chemotherapy combined with HER2-directed therapy. The current diagnostic assays have poor positive-predictive accuracy in identifying therapy-responsive breast cancers. Here, we deployed quantitative single molecule localization microscopy to assess the molecular features of HER2 in a therapy-responsive setting. Using fluorescently labeled trastuzumab as a probe, we first compared the molecular features of HER2 in trastuzumab-sensitive (BT-474 and SK-BR-3) and trastuzumab-resistant (BT-474R and JIMT-1) cultured cell lines. Trastuzumab-sensitive cells had significantly higher detected HER2 densities and clustering. We then evaluated HER2 in pre-treatment core biopsies from women with breast cancer undergoing neoadjuvant therapy. A complete pathological response was associated with a high detected HER2 density and significant HER2 clustering. These results established the nano-organization of HER2 as a potential signature of therapy-responsive disease.

27 January 2024 in Cancers
Verified
Journal Article
Open access
PDF file
KMKavitha Mukund
Kavitha Mukund
JAJackelyn Ann Alva-Ornelas
Jackelyn Ann Alva-Ornelas
Adam Lee MaddoxAdam Lee Maddox
Adam Lee Maddox
DMDivya Murali
Divya Murali
DVDarya Veraksa
Darya Veraksa
SSShankar Subramaniam
Shankar Subramaniam
Trastuzumab therapy in HER2+ breast cancer patients has mixed success owing to acquired resistance to therapy. A detailed understanding of downstream molecular cascades resulting from trastuzumab resistance is yet to emerge. In this study, we investigate the cellular mechanisms underlying acquired resistance using trastuzumab-sensitive and -resistant cancer cells (BT474 and BT474R) treated with endogenous ligands EGF and HRG across time. We probe early receptor organization through microscopy and signaling events through multiomics measurements and assess the bioenergetic state through mitochondrial measurements. Integrative analyses of our measurements reveal significant alterations in EGF-treated BT474 HER2 membrane dynamics and robust downstream activation of PI3K/AKT/mTORC1 signaling. EGF-treated BT474R shows a sustained interferon-independent activation of the IRF1/STAT1 cascade, potentially contributing to trastuzumab resistance. Both cell lines exhibit temporally divergent metabolic demands and HIF1A-mediated stress responses. BT474R demonstrates inherently increased mitochondrial activity. HRG treatment in BT474R leads to a pronounced reduction in AR expression, affecting downstream lipid metabolism with implications for treatment response. Our results provide novel insights into mechanistic changes underlying ligand treatment in BT474 and BT474R and emphasize the pivotal role of endogenous ligands. These results can serve as a framework for furthering the understanding of trastuzumab resistance, with therapeutic implications for women with acquired resistance.